通过使用Deep ResUnet和Efficientnet进行有效的阿尔茨海默病细分和分类
Battula Srinivasa Rao1, Mudiyala Aparna1, Jonnadula Harikiran1
1School of Computer Science and Engineering, VIT-AP University, Amravathi, India.
Journal of biomolecular structure & dynamics
|December 20, 2023
概括
这项研究介绍了一种先进的AI系统,用于使用MRI扫描进行早期阿尔茨海默病 (AD) 检测. 这种新的方法在AD阶段的分类中实现了高精度,提高了诊断能力.
科学领域:
- 神经学 神经学
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特点是脑细胞的逐渐衰弱和认知能力下降.
- 早期诊断AD对于有效的患者护理和治疗至关重要,但传统方法面临局限性.
- 需要先进的图像分析技术来准确和早期检测AD.
研究的目的:
- 使用磁共振成像 (MRI) 开发一种精确有效的阿尔茨海默病 (AD) 识别系统.
- 利用深度学习和高级特征提取来改善AD诊断.
- 为了高精度地分类阿尔茨海默病的阶段.
主要方法:
- 大脑MRI图像使用基于Deep ResUnet的方法进行细分.
- 全球和本地特征通过多尺度注意力语网络 (MASNet) 提取.
- 使用Slime Mold算法进行特征选择,然后使用EfficientNetB7.7进行分类.
主要成果:
- 提出的方法在阿尔茨海默病 (AD) 分类方面取得了高准确性.
- 在Kaggle和ADNI数据集上进行测试,该系统的准确性分别为99.31%和99.38%.
- 结果表明,该系统对于准确的AD分期的有效性.
结论:
- 开发的人工智能驱动系统为阿尔茨海默病 (AD) 诊断提供了高度准确和高效的方法.
- 这种方法显示了提高临床环境中早期检测和患者管理的巨大潜力.
- 该研究强调了综合深度学习技术在神经退行性疾病分类中的有用性.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492


